Monday, June 27, 2022
News

Rare bleeding disorder patients in India to get 1st preventive treatment (Lead)

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | Tuesday, 2022 2:15:09 AM IST
A US FDA-approved treatment that may prevent haemophilia, a rare bleeding disorder, has been launched in India for the first time, global biopharmaceutical company Takeda Pharmaceutical said on Monday.

A genetic condition that prevents blood from clotting, haemophilia causes bleeding for a long time after injury or surgery and painful swelling of the joints either after injury or even without injury.

In India, more than 1,36,000 people have been diagnosed with the disorder that causes lifelong bleeding, and has so far no known cure.

The prophylaxis treatment is named Adynovate and is an innovative extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology (controlled PEGylation), for haemophilia A patients.

Adynovate, in combination with MYPKFIT, is an FDA approved application that offers personalised and interactive prophylaxis treatment option that enables both healthcare professionals (HCPs) and patients in real-time monitoring, the company said in a statement.

Alerts are sent to patients on prophylaxis when their estimated factor VIII levels are low, and reminds them when their infusions are due, thereby providing excellent prophylactic coverage.

The drug is available in India post all necessary clinical trials, the company said, adding it has also taken requisite approvals including from Indian regulatory bodies such as the DCGI, and the CDSCO.

"Individuals with severe haemophilia have recurrent hemarthrosis - fragmentation of joint cartilage, bone destruction, and crippling, which can be effectively reduced through prophylaxis as opposed to on-demand therapy," Dr. Sandeep Arora, Head of Medical Affairs and Patient Services, Takeda India, in a statement.

Adynovate has demonstrated "favourable safety and efficacy results that offer effective bleed resolution, better joint health, and almost zero spontaneous bleeds in majority", he added.

--IANS rvt/vd

( 291 Words)

2022-05-16-20:00:02 (IANS)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Study reveals undiagnosed major risk fac...
Centre has allocated over Rs 2,600cr to ...
Typhoid bacteria increasingly resistant ...
Flu vax linked to 40% reduced risk of Al...
Research discovers benefits of exercise ...
Marital education benefits people's over...
More...
 
INDIA WORLD ASIA
Guwahati: Rebel Sena MLAs hold meeting; ...
7 arrested for cheating over 250 through...
64kg ganja seized in Gurugram, two held...
Dismal show in Tripura by-polls leaves T...
Sreekumar, Teesta sent to 5 days police ...
Apple to launch variety of new gadgets s...
More...    
 
 Top Stories
Singapore Airlines capacity up 126 ... 
Knocks by Hooda, Hardik guide India... 
Israel's unruly coalition has colla... 
Sundance winner 'Utama' wins top pr... 
Saudi crown prince, Iraqi PM meet o... 
Research discovers benefits of exer... 
PM Modi's diplomatically packed two... 
4 million women in Karachi deprived...